BioSpace News Archive

Greenwich LifeSciences, Inc. announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement.

Shattuck Labs, Inc. announced updated interim data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.

Zura Bio Limited, a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab, for the treatment of Sjogren’s syndrome.

Bio-Path Holdings, Inc. presented interim results from the Company’s Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia in a poster presentation at 2024 European Hematology Association Congress, on June 14, 2024 in Madrid, Spain.

Renalytix plc announces that on June 13, 2024 Medicare issued a final Local Coverage Determination for the Company’s kidneyintelX.dkd testing.

Editas Medicine, Inc., a clinical-stage genome editing company, announced new safety and efficacy data in 18 patients living with sickle cell disease treated with renizgamglogene autogedtemcel in the Phase 1/2/3 RUBY clinical trial.

Rigel Pharmaceuticals, Inc. announced one oral and four poster presentations at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.

Pfizer Inc. announced detailed overall survival results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ in patients with heavily pretreated relapsed or refractory multiple myeloma.

Protagonist Therapeutics, Inc. announced details from two abstracts at the European Hematology Association 2024 Congress, including an oral presentation with long-term follow-up data from the Phase 2 REVIVE study with rusfertide, a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera and other disease indications.

Sun Pharma and Israel-based Moebius Medical Limited presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II.